2. Search Result
Search Result
Results for "

cataract

" in MedChemExpress (MCE) Product Catalog:

31

Inhibitors & Agonists

3

Biochemical Assay Reagents

2

Peptides

5

Natural
Products

2

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-133026
    N-Acetylcarnosine

    N-Acetyl-L-carnosine

    		 Drug Intermediate Endogenous Metabolite Inflammation/Immunology
    N-Acetylcarnosine, a natural histidine-containing dipeptide, is a source of pharmacological principal L-carnosine. N-Acetylcarnosine is a potent ophthalmic agent in human cataracts .
    N-Acetylcarnosine
  • HY-10016
    E 2012
    5+ Cited Publications

    		 γ-secretase Neurological Disease
    E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing. E 2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. E 2012 aims at Alzheimer's disease by reduction of amyloid β-42, and induces cataract following repeated doses in the rat .
    E 2012
  • HY-19696B
    Tauroursodeoxycholate dihydrate
    100+ Cited Publications

    Tauroursodeoxycholic acid dihydrate; TUDCA dihydrate; UR 906 dihydrate

    		 Caspase Apoptosis Endogenous Metabolite IRE1 NF-κB JNK Reactive Oxygen Species (ROS) Akt Neurological Disease Metabolic Disease Inflammation/Immunology
    Tauroursodeoxycholate dehydrate is an orally active taurine conjugate of Ursodeoxycholic acid (HY-13771). Tauroursodeoxycholate dehydrate inhibits caspase-3/7, Apoptosis, IRE1α/TRAF2/NF-κB, prevents JNK phosphorylation, inhibits ROS generation, and activates Akt signaling. Tauroursodeoxycholate dehydrate prevents cataract formation, reduces renal tubular damage in type 2 diabetic mice, reduces I/R injury in liver, and inhibits intestinal inflammation and barrier disruption in nonalcoholic fatty liver disease .
    Tauroursodeoxycholate dihydrate
  • HY-108296
    Pirenoxine

    Catalin K

    		 Reactive Oxygen Species (ROS) Metabolic Disease
    Pirenoxine (Catalin K) is a potent antioxidant. Pirenoxine shows anti-presbyopic activity. Pirenoxine has the potential for the research of cataracts .
    Pirenoxine
  • HY-66012
    Proparacaine hydrochloride
    2 Publications Verification

    Proxymetacaine hydrochloride

    		 Sodium Channel Neurological Disease
    Proparacaine (Proxymetacaine) hydrochloride is a local anesthetic. Proparacaine hydrochloride blocks voltage-gated sodium channels on neuronal cell membranes, thereby inhibiting signal conduction and nociceptive signal transmission. Proparacaine hydrochloride blocks nociceptive signals in the eye and induces ocular muscle relaxation to reduce eye movement during surgery. Proparacaine hydrochloride is used in research related to cataracts .
    Proparacaine hydrochloride
  • HY-151231
    6-Hydroxyluteolin

    		Aldose Reductase Neurological Disease Metabolic Disease
    6-Hydroxyluteolin (Compound 17) is a flavonoid derivative and also an inhibitor of Aldose reductase, with an experimental -log IC50 value of 6.690. 6-Hydroxyluteolin can be isolated from the leaves of multiple plant families, including Plantaginaceae, Globulariaceae and Labiatae. 6-Hydroxyluteolin serves as a phylogenetic marker for higher plants. 6-Hydroxyluteolin can be used in the research of diabetic cataract .
    6-Hydroxyluteolin
  • HY-B0400B
    D-Sorbitol, for cell culture

    Sorbito, for cell culture; D-Glucitol, for cell culture

    		 Environmental Pollutants Biochemical Assay Reagents Others
    D-Sorbitol (D-Glucitol), for cell culture is a six-carbon sugar alcohol that can be used as a sugar substitute. D-Sorbitol, for cell culture serves as an osmotic regulator, cryoprotectant and carbon source in various plant and microbial cell culture media .
    D-Sorbitol, for cell culture
  • HY-118933
    Calpain Inhibitor VI
    1 Publications Verification

    SJA6017

    		 Proteasome Others
    Calpain Inhibitor VI (SJA6017) is a synthesized peptide aldehyde inhibitor of calpain. Calpain Inhibitor VI inhibits purified m-calpain with the IC50 of 80 nM. Calpain Inhibitor VI can be used for the research of cataract .
    Calpain Inhibitor VI
  • HY-113033
    Pentosidine

    		Others Biochemical Assay Reagents Neurological Disease Metabolic Disease Inflammation/Immunology
    Pentosidine is a fluorescent advanced glycation end product (AGE) and cross-linker. Pentosidine is a fluorescent cross-linked structure formed by lysine and arginine in sugar oxidation reactions, and it is commonly found in collagen, skin, bone, lens and plasma proteins . Pentosidine is used in research related to type 1 diabetes, brown cataracts, rheumatoid arthritis, atherosclerosis and neurodegenerative diseases .
    Pentosidine
  • HY-N8318
    Luteolin-3′,7-diglucoside

    		Others Infection
    Luteolin-3′,7-diglucoside is a glycoside that can be isolated from R. luteolin. Luteolin-3′,7-diglucoside significantly inhibits cataracts induced in ovine lenses. Luteolin-3′,7-diglucoside inhibits the activity of Ureaplasma urealyticumATCC and clinical strains .
    Luteolin-3′,7-diglucoside
  • HY-Y0785
    Glyoxal (40% w/w in water)

    		Drug Metabolite Metabolic Disease
    Glyoxal is a cytotoxic α-oxoaldehyde. Glyoxal induces cell damage and promotes protein glycation to form advanced glycation end-products (AGEs). Glyoxal is promising for research of oxidative stress-related diseases (such as atherosclerosis, cataract, Alzheimer's disease), and the formation of calcium oxalate kidney stones .
    Glyoxal (40% w/w in water)
  • HY-122963
    Danshenol B

    		Adenosine Receptor Metabolic Disease
    Danshenol B is a diterpenoid. Danshenol B has strong aldose reductase (AR) inhibitory activity with IC50 value of 0.042μM. Danshenol B can be used for the research of diabetic related complication resulted by metabolic abnormality, such as cataracts, retinopathy, neuropathy, and nephropathy .
    Danshenol B
  • HY-B2165
    Bendazac L-Lysine
    2 Publications Verification

    		 Amino Acid Derivatives Others
    Bendazac L-Lysine is one of agents that have been introduced for the management of cataracts, protecting the level of vision in patients, thus delaying the need for surgical intervention.
    Bendazac L-Lysine
  • HY-Y0785S
    Glyoxal-d2

    		Isotope-Labeled Compounds Drug Metabolite Metabolic Disease
    Glyoxal-d2 is the deuterium labeled Glyoxal (HY-Y0785). Glyoxal is a cytotoxic α-oxoaldehyde. Glyoxal induces cell damage and promotes protein glycation to form advanced glycation end-products (AGEs). Glyoxal is promising for research of oxidative stress-related diseases (such as atherosclerosis, cataract, Alzheimer's disease), and the formation of calcium oxalate kidney stones .
    Glyoxal-d2
  • HY-112573A
    Azapentacene sodium

    Quinax sodium; Phacolysine sodium

    		 Biochemical Assay Reagents Metabolic Disease
    Azapentacene sodium is an anti-cataract agent .
    Azapentacene sodium
  • HY-W601605
    Methosorbinil

    		Aldose Reductase Endocrinology
    Methosorbinil is an aldose reductase inhibitor with anti-cataract activity .
    Methosorbinil
  • HY-185048
    PCB-OAA

    		Drug Intermediate Neurological Disease
    PCB-OAA is a biocompatible multivinyl polycarboxybetaine macromonomer and that exhibits anti-fouling activity. PCB-OAA can form a hydrogel in vitreous cavity and shows an appealing ability to prevent significantly inflammatory response, fibrosis and complications such as raised intraocular pressure, and cataract formation. PCB-OAA can be used for the research of vitreous substitution .
    PCB-OAA
  • HY-W795259
    L-Val-P

    		MMP Infection Inflammation/Immunology Cancer
    L-Val-P is a potent leucine aminopeptidase (LAP) inhibitor with a Ki of 0.15 μM. L-Val-P is promising for research of HIV infection, inflammation, eye lens cataract and cancer .
    L-Val-P
  • HY-106198
    Lidorestat

    IDD-676

    		 Aldose Reductase Metabolic Disease
    Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation .
    Lidorestat
  • HY-133026R
    N-Acetylcarnosine (Standard)

    N-Acetyl-L-carnosine (Standard)

    		 Drug Intermediate Endogenous Metabolite Reference Standards Inflammation/Immunology
    N-Acetylcarnosine (Standard) is the analytical standard of N-Acetylcarnosine. This product is intended for research and analytical applications. N-Acetylcarnosine, a natural histidine-containing dipeptide, is a source of pharmacological principal L-carnosine. N-Acetylcarnosine is a potent ophthalmic agent in human cataracts .
    N-Acetylcarnosine (Standard)
  • HY-106317
    Glutathione monoisopropyl ester

    Glutathione isopropyl ester; YM 737

    		 Drug Derivative Neurological Disease Inflammation/Immunology Cancer
    Glutathione monoisopropyl ester (Glutathione isopropyl ester) is an ester derivative of glutathione. Glutathione monoisopropyl ester can increase glutathione concentrations in tissues such as the liver, lungs, heart, and brain of mice, exerting a dose-dependent protective effect against liver injury. Glutathione monoisopropyl ester effectively inhibits ultraviolet-induced lipid peroxidation, inflammatory responses, and tumorigenesis in the skin of hairless mice by maintaining epidermal glutathione levels. Glutathione monoisopropyl ester also inhibits the progression of X-ray-induced cataracts in rats .
    Glutathione monoisopropyl ester
  • HY-121892
    (Z)-KC02

    		TNF Receptor Neurological Disease
    (Z)-KC02 is an inhibitor of ABHD16A, the phosphatidylserine (PS) lipase that produces lyso-PS. Lysophosphatidylserine (lyso-PS) is a signaling lipid that regulates immune and neurological processes. It is associated with several neurological disorders such as retinitis pigmentosa and cataracts (PHARC). (Z)-KC02 depletes lyso-PS in lymphoblasts from PHARC subjects. (Z)-KC02 also reduces lyso-PS and lipopolysaccharide-induced cytokine production in macrophages and modulates lyso-PS metabolism in vivo .
    (Z)-KC02
  • HY-149596
    PTZ-LD

    		Fluorescent Dye Metabolic Disease
    PTZ-LD is a phenothiazine (HY-Y0055)-based fluorescent probe for lipid droplets (LDs) detection. PTZ-LD is apparently emissive in LDs with high specificity. (Ex/Em=488/570-620 nm). PTZ-LD can be used for diabetic cataract (DC) research .
    PTZ-LD
  • HY-N9335
    Myrciacetin

    		Aldose Reductase Neurological Disease
    Myrciacetin is a flavonoid from Rhododendron dauricum. Myrciacetin is against rat lens aldose reductase with an IC50 of 13 μM .
    Myrciacetin
  • HY-66012R
    Proparacaine hydrochloride (Standard)

    Proxymetacaine hydrochloride (Standard)

    		 Reference Standards Sodium Channel Neurological Disease
    Proparacaine (Hydrochloride) (Standard) is the analytical standard of Proparacaine (Hydrochloride). This product is intended for research and analytical applications. Proparacaine hydrochloride is a local anesthetic. Proparacaine hydrochloride blocks voltage-gated sodium channels on neuronal cell membranes, thereby inhibiting signal conduction and nociceptive signal transmission. Proparacaine hydrochloride blocks nociceptive signals in the eye and induces ocular muscle relaxation to reduce eye movement during surgery. Proparacaine hydrochloride is used in research related to cataracts.
    Proparacaine hydrochloride (Standard)
  • HY-B1888AS
    Bromfenac-d4 sodium

    		Isotope-Labeled Compounds COX Inflammation/Immunology
    Bromfenac-d4 (sodium) is deuterium labeled Bromfenac (sodium). Bromfenac sodium is a potent and orally active inhibitor of COX, with IC50s of 5.56 and 7.45 nM for COX-1 and COX-2, respectively. Bromfenac sodium is a brominated non-steroidal anti-inflammatory/analgesic agent (NSAID), and it is commonly used for the research of postoperative inflammation and pain following cataract surgery, and pseudophakic cystoid macular edema (CME) .
    Bromfenac-d4 sodium
  • HY-106198R
    Lidorestat (Standard)

    IDD-676 (Standard)

    		 Reference Standards Aldose Reductase Metabolic Disease
    Lidorestat (Standard) is the analytical standard of Lidorestat (HY-106198). This product is intended for research and analytical applications. Lidorestat (IDD-676) is a potent, selective and orally active aldose reductase inhibitor with an IC50 of 5 nM. Lidorestat can be used for chronic diabetes complications. Lidorestat also improves nerve conduction and reduces cataract formation .
    Lidorestat (Standard)
  • HY-183855
    WF-2421

    		Aldose Reductase Neurological Disease Metabolic Disease Inflammation/Immunology Endocrinology
    WF-2421 is an aldose reductase inhibitor with an IC50 of 0.03 μM against rabbit-derived aldose reductase. WF-2421 acts as a non-competitive inhibitor of aldose reductase using dl-glyceraldehyde as the substrate. WF-2421 can be used in the research of diabetic complications (cataract, neuropathy, retinopathy, nephropathy) .
    WF-2421
  • HY-B2165R
    Bendazac L-Lysine (Standard)

    		Amino Acid Derivatives Reference Standards Others
    Bendazac L-Lysine (Standard) is the analytical standard of Bendazac L-Lysine. This product is intended for research and analytical applications. Bendazac L-Lysine is one of agents that have been introduced for the management of cataracts, protecting the level of vision in patients, thus delaying the need for surgical intervention.
    Bendazac L-Lysine (Standard)
  • HY-66012A
    Proparacaine

    Proxymetacaine

    		 Sodium Channel Neurological Disease
    Proparacaine (Proxymetacaine) is a local anesthetic. Proparacaine blocks voltage-gated sodium channels on neuronal cell membranes, thereby inhibiting signal conduction and nociceptive signal transmission. Proparacaine blocks nociceptive signals in the eye and induces ocular muscle relaxation to reduce eye movement during surgery. Proparacaine is used in research related to cataracts .
    Proparacaine
  • HY-10016R
    E 2012 (Standard)

    		γ-secretase Reference Standards Neurological Disease
    E 2012 (Standard) is the analytical standard of E 2012 (HY-10016). This product is intended for research and analytical applications. E 2012 is a potent gamma (γ) secretase modulator without affecting Notch processing. E 2012 inhibits 3β-hydroxysterol Δ24-reductase (DHCR24) at the final step in the cholesterol biosynthesis. E 2012 aims at Alzheimer's disease by reduction of amyloid β-42, and induces cataract following repeated doses in the rat .
    E 2012 (Standard)

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: